Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633552 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL30457465 | 0.86 | MEN1 (0.76) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL25633524 | 0.86 | MEN1 (0.76) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL11876925 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL9802946 | 0.81 | MAPT (1.00) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL8114973 | 0.80 | MEN1 (0.66) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL20020500 | 0.80 | MEN1 (0.69) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL5665907 | 0.79 | MEN1 (0.68) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL125016 | 0.79 | MEN1 (0.68) | MEN1KMT2AMAPTHSD17B10L3MBTL1 | |
| SCHEMBL7703374 | 0.78 | MAPT (1.00) | MEN1KMT2AMAPTHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051314-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | PARIS SCIENCES ET LETTRES (FR) | 2025-02-13 | — | — | US | disclosed |
| EP-4444308-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | Institut Curie (FR) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023104976-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | INSTITUT CURIE (FR) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051314-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | STAT1, IFNG, IRF2BP2 | MEN1 3227/4885KMT2A 2840/4885MAPT 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.